A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice

Vaccine

Volumn 27, Issue 23, 2009, Pages 3026-3034

  Hwang, Shen An ^a   Wilk, Katarzyna ^a   Kruzel, Marian L ^a   Actor, Jeffrey K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; BCG; Lactoferrin; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; CYTOKINE; LACTOFERRIN; TMC 1011; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLYCOSYLATION; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOMODULATION; LUNG INJURY; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; CARRIER PROTEINS; HUMANS; IMMUNITY, CELLULAR; MICE; MYCOBACTERIUM TUBERCULOSIS; PULMONARY ALVEOLI; RECOMBINANT PROTEINS; TUBERCULOSIS, PULMONARY;

EID: 67349256155     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.036     Document Type: Article

References (60)

1. Oettinger T., Jorgensen M., Ladefoged A., Haslov K., and Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 79 4 (1999) 243-250
2. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2 February (2) (2002) 86-92
3. Maher D., and Raviglione M. Global epidemiology of tuberculosis. Clin Chest Med 26 June (2) (2005) 167-82, v
4. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 July (1 Pt 1) (1995) 29-35
5. Sterne J.A., Rodrigues L.C., and Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 2 March (3) (1998) 200-207
6. Doherty T.M. Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 23 March 18 (17-18) (2005) 2109-2114
7. Girard M.P., Fruth U., and Kieny M.P. A review of vaccine research and development: tuberculosis. Vaccine 23 December (50) (2005) 5725-5731
8. McMurray D.N. A coordinated strategy for evaluating new vaccines for human and animal tuberculosis. Tuberculosis (Edinb) 81 1-2 (2001) 141-146
9. Hudgens M.G., and Halloran M.E. Causal vaccine effects on binary postinfection outcomes. J Am Stat Assoc 101 Mar (473) (2006) 51-64
10. Locht C., Rouanet C., Hougardy J.M., and Mascart F. How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis. Expert Opin Biol Ther 7 November (11) (2007) 1665-1677
11. Glyn Hewinson R. TB vaccines for the World. Tuberculosis (Edinb) 85 January-March (1-2) (2005) 1-6
12. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 December (25) (2000) 13853-13858
13. Kaufmann S.H. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 26 December (12) (2005) 660-667
14. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
15. Flynn J.L. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84 1-2 (2004) 93-101
16. Rook G.A., Dheda K., and Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine 23 March (17-18) (2005) 2115-2120
17. Gupta U.D., Katoch V.M., and McMurray D.N. Current status of TB vaccines. Vaccine 25 May (19) (2007) 3742-3751
18. Rook G.A., Hernandez-Pando R., Dheda K., and Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 September (9) (2004) 483-488
19. Vogel F.R. Improving vaccine performance with adjuvants. Clin Infect Dis 30 June (Suppl. 3) (2000) S266-S270
20. Dascher C.C., Hiromatsu K., Xiong X., Morehouse C., Watts G., Liu G., et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol 15 August (8) (2003) 915-925
21. McMurray D.N. Recent progress in the development and testing of vaccines against human tuberculosis. Int J Parasitol 33 May (5-6) (2003) 547-554
22. Haile M., Schroder U., Hamasur B., Pawlowski A., Jaxmar T., Kallenius G., et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22 March (11-12) (2004) 1498-1508
23. Chambers M.A., Wright D.C., Brisker J., Williams A., Hatch G., Gavier-Widen D., et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 22 February (8) (2004) 1063-1071
24. Hwang S.A., Wilk K.M., Budnicka M., Olsen M., Bangale Y.A., Hunter R.L., et al. Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. Vaccine 25 September (37-38) (2007) 6730-6743
25. Legrand D., Pierce A., Elass E., Carpentier M., Mariller C., and Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 606 (2008) 163-194
26. Baker E.N., and Baker H.M. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 62 November (22) (2005) 2531-2539
27. Chodaczek G., Saavedra-Molina A., Bacsi A., Kruzel M.L., Sur S., and Boldogh I. Iron-mediated dismutation of superoxide anion augments antigen-induced allergic inflammation: effect of lactoferrin. Postepy Hig Med Dosw (Online) 61 (2007) 268-276
28. Kruzel M.L., Actor J.K., Boldogh I., and Zimecki M. Lactoferrin in health and disease. Postepy Hig Med Dosw (Online) 61 (2007) 261-267
29. Hwang S.A., Kruzel M.L., and Actor J.K. Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages. Biochimie 91 1 (2009) 76-85
30. Hwang S.A., Wilk K.M., Bangale Y.A., Kruzel M.L., and Actor J.K. Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol 196 September (3) (2007) 171-180
31. Kruzel M.L., and Zimecki M. Lactoferrin and immunologic dissonance: clinical implications. Arch Immunol Ther Exp (Warsz) 50 6 (2002) 399-410
32. Kruzel M.L., Bacsi A., Choudhury B., Sur S., and Boldogh I. Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology 119 October (2) (2006) 159-166
33. Actor J.K., Hwang S.A., Olsen M., Zimecki M., Hunter Jr. R.L., and Kruzel M.L. Lactoferrin immunomodulation of DTH response in mice. Int Immunopharmacol 2 March (4) (2002) 475-486
34. Hwang S.A., Kruzel M.L., and Actor J.K. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int Immunopharmacol 5 March (3) (2005) 591-599
35. Zimecki M., Kapp J., Machnicki M., Zagulski T., Wlaszczyk A., Kubler A., et al. Lactoferrin. Its role in maturation and function of cells of the immune system and protection against shock in mice. Adv Exp Med Biol 443 (1998) 331-336
36. Zimecki M., and Kruzel M.L. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol Lett 74 November (3) (2000) 183-188
37. Wilk K.M., Hwang S.A., and Actor J.K. Lactoferrin modulation of antigen-presenting-cell response to BCG infection. Postepy Hig Med Dosw (Online) 61 (2007) 277-282
38. Choi B.K., Actor J.K., Rios S., d'Anjou M., Stadheim T.A., Warburton S., et al. Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj J 25 6 (2008) 581-593
39. Jagannath C., Lindsey D.R., Dhandayuthapani S., Xu Y., Hunter Jr. R.L., and Eissa N.T. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 15 3 (2009) 267-276
40. Copenhaver R.H., Sepulveda E., Armitige L.Y., Actor J.K., Wanger A., Norris S.J., et al. A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun 72 12 (2004) 7084-7095
41. Saalmuller A. New understanding of immunological mechanisms. Vet Microbiol 117 October (1) (2006) 32-38
42. Robinson H.L., and Amara R.R. T cell vaccines for microbial infections. Nat Med 11 April (4 Suppl.) (2005) S25-32
43. Young D.B., Perkins M.D., Duncan K., and Barry III C.E. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 118 April (4) (2008) 1255-1265
44. Padilla-Carlin D.J., McMurray D.N., and Hickey A.J. The guinea pig as a model of infectious diseases. Comp Med 58 August (4) (2008) 324-340
45. Hope J.C., and Villarreal-Ramos B. Bovine TB and the development of new vaccines. Comp Immunol Microbiol Infect Dis 31 March (2-3) (2008) 77-100
46. Hwang S.A., Kruzel M.L., and Actor J.K. Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages. Biochimie 91 January (1) (2009) 76-85
47. Beamer G.L., Flaherty D.K., Vesosky B., and Turner J. Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol 15 March (3) (2008) 474-483
48. Saunders B.M., Frank A.A., Orme I.M., and Cooper A.M. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 68 June (6) (2000) 3322-3326
49. Rook G.A. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 7 May (3) (2007) 327-337
50. Baldwin S.L., D'Souza C., Roberts A.D., Kelly B.P., Frank A.A., Lui M.A., et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66 June (6) (1998) 2951-2959
51. Orme I.M., McMurray D.N., and Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol 9 March (3) (2001) 115-118
52. Legrand D., Elass E., Carpentier M., and Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 62 November (22) (2005) 2549-2559
53. Zimecki M., Artym J., Chodaczek G., Kocieba M., Kuryszko J., Houszka M., et al. Immunoregulatory function of lactoferrin in immunosuppressed and autoimmune animals. Postepy Hig Med Dosw (Online) 61 (2007) 283-287
54. Kim S.J., Yu D.Y., Pak K.W., Jeong S., Kim S.W., and Lee K.K. Structure of the human lactoferrin gene and its chromosomal localization. Mol Cells 8 December (6) (1998) 663-668
55. van Veen H.A., Geerts M.E., van Berkel P.H., and Nuijens J.H. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur J Biochem 271 February (4) (2004) 678-684
56. Thomassen E.A., van Veen H.A., van Berkel P.H., Nuijens J.H., and Abrahams J.P. The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin. Transgenic Res 14 August (4) (2005) 397-405
57. Nandi S., Yalda D., Lu S., Nikolov Z., Misaki R., Fujiyama K., et al. Process development and economic evaluation of recombinant human lactoferrin expressed in rice grain. Transgenic Res 14 June (3) (2005) 237-249
58. Heegaard N.H., and Brimnes J. Comparison of heparin-binding to lactoferrin from human milk and from human granulocytes by means of affinity capillary electrophoresis. Electrophoresis 17 December (12) (1996) 1916-1920
59. Moguilevsky N., Retegui L.A., and Masson P.L. Comparison of human lactoferrins from milk and neutrophilic leucocytes. Relative molecular mass, isoelectric point, iron-binding properties and uptake by the liver. Biochem J 229 July (2) (1985) 353-359
60. Weis W.I., Taylor M.E., and Drickamer K. The C-type lectin superfamily in the immune system. Immunol Rev 163 June (1998) 19-34